Literature DB >> 30790204

A Real-World Study on Antidepressant-Associated Sexual Dysfunction in 2144 Outpatients: The SALSEX I Study.

Angel L Montejo1,2, Julia Calama3,4, Fernando Rico-Villademoros5, Laura Montejo6, Nerea González-García3,7, Jesús Pérez8.   

Abstract

The objective of this cross-sectional study was to evaluate the frequency, impact, and management of sexual dysfunction associated with commonly prescribed antidepressants available in psychiatry outpatient clinics in Spain. We recruited 2163 adult patients who had undergone treatment with antidepressants for at least 8 weeks and had a history of normal sexual functioning before the prescription of the antidepressant, except for mildly impaired libido. We used the Psychotropic-Related Sexual Dysfunction Questionnaire (PRSexDQ-SALSEX) for evaluating the frequency and tolerance of sexual dysfunction and whether this side effect was spontaneously reported. Overall, 79% patients showed sexual dysfunction, as indicated by a total score ≥ 3 on the PRSexDQ-SALSEX; 64% showed moderate-severe sexual dysfunction, with no differences between men and women on these outcomes. In the multivariate logistic regression analysis, treatment with a serotonergic antidepressant and having a severe clinical state of psychiatric illness were the factors associated with the highest likelihood of presenting with sexual dysfunction. Sexual dysfunction was spontaneously reported by 838 (41%) of the 2066 evaluable patients for this outcome. Among patients with sexual dysfunction, this condition was poorly tolerated by 22% of the patients, with these frequencies being significantly higher in men than in women. The most frequently used strategies employed by the psychiatrists in our study for dealing with sexual dysfunction were switching to another antidepressant (34%) and waiting for spontaneous resolution (33%). In conclusion, our results indicate that despite being a well-known, long-standing side effect of antidepressants, sexual dysfunction continues to be extremely common in patients receiving antidepressants, especially serotonergic ones, potentially jeopardizing treatment success in a substantial proportion of patients. There are important sex differences in the reporting and tolerance of sexual dysfunction that require further investigation.

Entities:  

Keywords:  Antidepressant; Psychotropic; Sex differences; Sexual dysfunction; Sexual functioning

Mesh:

Substances:

Year:  2019        PMID: 30790204     DOI: 10.1007/s10508-018-1365-6

Source DB:  PubMed          Journal:  Arch Sex Behav        ISSN: 0004-0002


  6 in total

1.  Antidepressant Use During Development May Impair Women's Sexual Desire in Adulthood.

Authors:  Tierney K Lorenz
Journal:  J Sex Med       Date:  2020-01-11       Impact factor: 3.802

2.  Sex differences in pharmacological treatment of major depressive disorder: results from the AMSP pharmacovigilance program from 2001 to 2017.

Authors:  Johanna Seifert; Fabienne Führmann; Marcel Sieberer; Waldemar Greil; Matthias A Reinhard; Rolf R Engel; Xueqiong Bernegger; Stefan Bleich; Susanne Stübner; Eckart Rüther; Sermin Toto; Renate Grohmann
Journal:  J Neural Transm (Vienna)       Date:  2021-05-11       Impact factor: 3.575

Review 3.  Management Strategies for Antidepressant-Related Sexual Dysfunction: A Clinical Approach.

Authors:  Angel L Montejo; Nieves Prieto; Rubén de Alarcón; Nerea Casado-Espada; Javier de la Iglesia; Laura Montejo
Journal:  J Clin Med       Date:  2019-10-07       Impact factor: 4.241

4.  Occurrence of Side Effects in Treatment-Resistant Depression: Role of Clinical, Socio-Demographic and Environmental Characteristics.

Authors:  Anna Levy; Wissam El-Hage; Djamila Bennabi; Etienne Allauze; Alexandra Bouvard; Vincent Camus; Philippe Courtet; Jean-Michel Dorey; Bruno Etain; Guillaume Fond; Jean-Baptiste Genty; Jérôme Holtzmann; Mathilde Horn; Marion Leboyer; Pierre-Michel Llorca; Manon Meyrel; Fanny Molière; Anne-Sophie Nguon; Jean Petrucci; Romain Rey; Raphaelle Richieri; Florian Stephan; Guillaume Vaiva; Michel Walter; Emmanuel Haffen; Bruno Aouizerate; Antoine Yrondi
Journal:  Front Psychiatry       Date:  2021-12-06       Impact factor: 4.157

5.  Efficacy and safety of Morinda officinalis oligosaccharide capsules for depressive disorder: a systematic review and meta-analysis.

Authors:  Yun Du; Qin Zheng; Zheng-Hang Ou; Yu-Jia Cao; Xiao-Peng Su; Chunbo Li; Miao Qu
Journal:  Braz J Psychiatry       Date:  2020-09-28       Impact factor: 2.697

6.  Sexuality and Mental Health: The Need for Mutual Development and Research.

Authors:  Angel L Montejo
Journal:  J Clin Med       Date:  2019-10-26       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.